470 related articles for article (PubMed ID: 11591843)
1. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
4. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
Rao AB; Richert N; Howard T; Lewis BK; Bash CN; McFarland HF; Frank JA
Neurology; 2002 Sep; 59(5):688-94. PubMed ID: 12221158
[TBL] [Abstract][Full Text] [Related]
5. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
Perumal JS; Caon C; Hreha S; Zabad R; Tselis A; Lisak R; Khan O
Eur J Neurol; 2008 Jul; 15(7):677-80. PubMed ID: 18459972
[TBL] [Abstract][Full Text] [Related]
6. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
[TBL] [Abstract][Full Text] [Related]
8. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
9. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
[TBL] [Abstract][Full Text] [Related]
11. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
12. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
Fox RJ; Fisher E; Tkach J; Lee JC; Cohen JA; Rudick RA
Mult Scler; 2005 Apr; 11(2):140-5. PubMed ID: 15794385
[TBL] [Abstract][Full Text] [Related]
13. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
14. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Burton JM; O'Connor PW; Hohol M; Beyene J
Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
[TBL] [Abstract][Full Text] [Related]
15. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
16. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
Di Gregorio M; Gaetani L; Eusebi P; Floridi P; Picchioni A; Rosi G; Mancini A; Floridi C; Baschieri F; Gentili L; Sarchielli P; Calabresi P; Di Filippo M
J Neurol; 2018 Mar; 265(3):522-529. PubMed ID: 29327284
[TBL] [Abstract][Full Text] [Related]
18. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
[TBL] [Abstract][Full Text] [Related]
19. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
20. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
Rudick RA; Cutter G; Baier M; Fisher E; Dougherty D; Weinstock-Guttman B; Mass MK; Miller D; Simonian NA
Neurology; 2001 May; 56(10):1324-30. PubMed ID: 11376182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
